Cargando…

696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies

BACKGROUND: Cefiderocol (S-649266, CFDC) is a novel siderophore cephalosporin with activity against a wide variety of Gram-negative bacteria including carbapenem-resistant strains. We previously reported that CFDC is efficiently transported into Pseudomonas aeruginosa via iron transporter PiuA. In t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Akinobu, Nishikawa, Toru, Ishii, Ryuta, Kuroiwa, Miho, Ishioka, Yoshino, Kurihara, Naoko, Sakikawa, Ikue, Ota, Takeshi, Rokushima, Masatomo, Tsuji, Masakatsu, Sato, Takafumi, Yamano, Yoshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254112/ http://dx.doi.org/10.1093/ofid/ofy210.703

Ejemplares similares

723. Synergistic Effect of Cefiderocol Combined With Other Antibiotics Against Cefiderocol High MIC Isolates From the Multi-National SIDERO-WT Studies
por: Yamano, Yoshinori, et al.
Publicado: (2019)

1366. In Vitro and In Vivo Activity of Cefiderocol against Stenotrophomonas maltophilia Clinical Isolates
por: Ito, Akinobu, et al.
Publicado: (2018)

Good Correlation of Cefiderocol Between In Vivo Efficacy Murine Thigh/Lung Infection Models and MIC Determined in Iron-Depleted Conditions
por: Yamano, Yoshinori, et al.
Publicado: (2017)

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
por: Ito, Akinobu, et al.
Publicado: (2019)

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
por: Ito, Akinobu, et al.
Publicado: (2018)

696. Cefiderocol Susceptibility Against Molecularly Characterized Carbapenemase-Producing Gram-Negative Bacteria in North America and Europe Between 2014 and 2017: SIDERO-WT-2014 to -2016 Studies
por: Sato, Takafumi, et al.
Publicado: (2019)

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
por: Ito, Akinobu, et al.
Publicado: (2016)

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study
por: Sato, Takafumi, et al.
Publicado: (2020)

Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Acinetobacter baumannii using in vitro chemostat and in vivo murine infection models
por: Gill, Christian M., et al.
Publicado: (2022)

1455. Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies
por: Yamano, Yoshinori, et al.
Publicado: (2020)

In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models
por: Nakamura, Rio, et al.
Publicado: (2019)

1349. Global Surveillance of Cefiderocol Against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
por: Tsuji, Masakatsu, et al.
Publicado: (2018)

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
por: Longshaw, Christopher, et al.
Publicado: (2020)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

In vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Track Source: SIDERO-WT-2014/SIDERO-WT-2015
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

In Vivo Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) against Gram-negative Bacteria in a Murine Thigh Model
por: Monogue, Marguerite, et al.
Publicado: (2017)

In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

2388. Efficacy of Humanized Cefiderocol Exposures Over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
por: Stainton, Sean, et al.
Publicado: (2018)

In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia
por: Nakamura, Rio, et al.
Publicado: (2021)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
por: Stainton, Sean M., et al.
Publicado: (2019)

1452. Molecular Profile of β-Lactamase Genes and Siderophore-Dependent Iron Transporter Genes of Cefiderocol High MIC Isolates from SIDERO-WT Studies
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

679. In vitro Activity of Cefiderocol (CFDC), a Novel Siderophore Cephalosporin, Against Difficult-to-Treat-Resistant (DTR) Gram-Negative Bacterial Pathogens From the Multi-National Sentinel Surveillance Study, SIDERO-WT (2014–2017)
por: Longshaw, Christopher, et al.
Publicado: (2019)

Targeted amplicon sequencing of wastewater samples for detecting SARS-CoV-2 variants with high sensitivity and resolution
por: Kuroiwa, Miho, et al.
Publicado: (2023)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
por: Hackel, Meredith A., et al.
Publicado: (2017)

Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model
por: Matsumoto, Shuhei, et al.
Publicado: (2020)

252 S-649266, a Novel Siderophore Cephalosporin: In vitro activity against Gram-negative bacteria
por: Tsuji, Masakatsu, et al.
Publicado: (2014)

NGC 1809 and PKS 0502-696
por: West, R M
Publicado: (1979)

Assessing drug target suitability using TargetMine
por: Chen, Yi-An, et al.
Publicado: (2019)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

692. In Vitro Antibacterial Activity of Cefiderocol Against a Multi-national Collection of Carbapenem-Nonsusceptible Gram-Negative Bacteria From Respiratory Infections: SIDERO-WT-2014–2017
por: Rao, Sonia N, et al.
Publicado: (2019)

XSL-FO
por: Pawson, Dave
Publicado: (2002)

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
por: Yamano, Yoshinori
Publicado: (2019)

Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing
por: Matuschek, Erika, et al.
Publicado: (2022)

LCZ696 ameliorates lipopolysaccharide-induced endothelial injury
por: Gao, Aihong, et al.
Publicado: (2021)

696. Bartonella quintana Endocarditis, A Case Series
por: Dieringer, Thomas D, et al.
Publicado: (2020)

1058. In Vitro and In Vivo Antibacterial Activity of Cefiderocol against Burkholderia spp
por: Oota, Merime, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_56e5btdg2r7prfooli2najnsk6